Cue Biopharma, Inc. Contracts & Agreements

Director Compensation Policy effective June 5, 2024 (Filed With SEC on November 14, 2024)

Second Amendment to Loan and Security Agreement, dated October 2, 2024, by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, and Cue Biopharma,... (Filed With SEC on October 4, 2024)

Underwriting Agreement, dated September 26, 2024, by and between Cue Biopharma, Inc. and Oppenheimer & Co. Inc., as representative of the underwriters named therein (Filed With SEC on September 27, 2024)

Form of Pre-Funded Warrant (Filed With SEC on September 27, 2024)

Form of Common Stock Warrant (Filed With SEC on September 27, 2024)

Form of stock option award under 2016 Omnibus Incentive Plan (Filed With SEC on August 14, 2024)

Form of stock option award under 2016 Non-Employee Equity Incentive Plan (Filed With SEC on August 14, 2024)

Description of Common Stock of the Registrant Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 28, 2024)

Director Compensation Policy effective December 7, 2023 (Filed With SEC on March 28, 2024)

Second Amendment to the Amended and Restated License Agreement with Albert Einstein College of Medicine dated January 13, 2024 (Filed With SEC on March 28, 2024)

Amendment No. 1 to Consulting Agreement between Cue Biopharma, Inc. and Peter A. Kiener, dated September 1, 2023 (Filed With SEC on November 3, 2023)

Amendment No. 2 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (Filed With SEC on August 8, 2023)

Amendment No. 1 to Cue Biopharma, Inc. 2016 Non-Employee Equity Incentive Plan (Filed With SEC on August 8, 2023)

Consulting Agreement effective June 7, 2023 entered into between Cue Biopharma, Inc. and Peter A Kiener, D.Phil (Filed With SEC on August 8, 2023)

Registration Rights Agreement, dated November 14, 2022, by and among the Company and the other parties thereto (Filed With SEC on November 15, 2022)

Form of Securities Purchase Agreement, dated November 14, 2022, by and among the Company and the other parties thereto (Filed With SEC on November 15, 2022)

Form of Warrant to Purchase Common Stock or Pre-Funded Warrant to be issued pursuant to the Securities Purchase Agreement (Filed With SEC on November 15, 2022)

Form of Pre-Funded Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement (Filed With SEC on November 15, 2022)

Termination of License Agreement, dated September 9, 2022, between Cue Biopharma, Inc. and MIL 21E, LLC (Filed With SEC on November 14, 2022)

Rider to License Agreement, dated as of July 7, 2022, between Cue Biopharma, Inc. and MIL 40G, LLC (Filed With SEC on August 4, 2022)

First Amendment to the License Agreement, dated May 3, 2022, between Cue Biopharma, Inc. and MIL 40G, LLC (Filed With SEC on August 4, 2022)

Director Compensation Policy dated January 1, 2021 (Filed With SEC on May 10, 2022)

License Agreement, March 28, 2022 (Filed With SEC on March 30, 2022)

Consulting Agreement, dated January 1, 2017, between the Registrant and Ken Pienta, as amended by Amendment No. 1 to Consulting Agreement dated December 15, 2021 (Filed With SEC on March 16, 2022)

Loan and Security Agreement, dated February 15, 2022, by and between Cue Biopharma, Inc. and Silicon Valley Bank (Filed With SEC on March 16, 2022)

Open Market Sale AgreementSM, dated October 1, 2021, by and between Cue Biopharma, Inc. and Jefferies LLC (Filed With SEC on November 9, 2021)

Third Amendment to License Agreement, dated October 22, 2021, by and between Cue Biopharma, Inc. and MIL 21E, LLC (Filed With SEC on November 9, 2021)

Open Market Sale AgreementSM, dated October 1, 2021, by and between Cue Biopharma, Inc. and Jefferies LLC (Filed With SEC on October 1, 2021)

Third Amendment to Collaboration, License and Option Agreement, dated October 29, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

First Amendment to Collaboration, License and Option Agreement, dated March 15, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

First Amendment to the Exclusive Patent License and Research Collaboration Agreement with Merck Sharp & Dohme Corp. dated November 9, 2020 (Filed With SEC on March 9, 2021)

Third Amended and Restated Executive Employment Agreement dated March 4, 2021 between the Company and Daniel Passeri (Filed With SEC on March 9, 2021)

Eighth Amendment to Collaboration, License and Option Agreement, dated December 7, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Seventh Amendment to Collaboration, License and Option Agreement, dated May 14, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Sixth Amendment to Collaboration, License and Option Agreement, dated February 14, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Fifth Amendment to Collaboration, License and Option Agreement, dated January 10, 2020, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Fourth Amendment to Collaboration, License and Option Agreement, dated December 18, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

Second Amendment to Collaboration, License and Option Agreement, dated August 5, 2019, between the Registrant and LG CHEM LTD (Filed With SEC on March 9, 2021)

First Amendment to the Amended and Restated License Agreement with Albert Einstein College of Medicine dated October 30, 2018 (Filed With SEC on March 9, 2021)

Third Amendment to Vivarium Agreement, dated July 20, 2020, between the Registrant and MIL 21E, LLC (Filed With SEC on November 9, 2020)

Executive Employment Agreement dated August 21, 2020 between the Company and Kerri-Ann Millar (Filed With SEC on August 24, 2020)

Second Amendment to License Agreement between the Registrant and MIL 21E, LLC (Filed With SEC on June 26, 2020)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated June 22, 2020 (Filed With SEC on June 22, 2020)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated March 27, 2020 (Filed With SEC on March 27, 2020)

Amendment No. 1 to Cue Biopharma, Inc. 2016 Omnibus Incentive Plan (Filed With SEC on March 12, 2020)

Description of Common Stock of the Registrant Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 12, 2020)

Second Amended and Restated Executive Employment Agreement dated February 10, 2020 between the Company and Daniel Passeri (Filed With SEC on February 10, 2020)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated November 25, 2019 (Filed With SEC on November 26, 2019)

Amended and Restated Executive Employment Agreement dated October 3, 2019 between the Company and Daniel Passeri (Filed With SEC on October 7, 2019)

Amended and Restated Executive Employment Agreement dated October 3, 2019 between the Company and Anish Suri (Filed With SEC on October 7, 2019)

At-the-Market Equity Offering Sales Agreement by and between Cue Biopharma, Inc. and Stifel, Nicolaus & Company, Incorporated, dated June 5, 2019 (Filed With SEC on June 5, 2019)

Director Compensation Policy dated October 30, 2018 (Filed With SEC on March 14, 2019)

Collaboration, License and Option Agreement, by and between the Company and LG Chem, Ltd., dated as of November 6, 2018 (Filed With SEC on December 26, 2018)

Collaboration, License and Option Agreement, by and between the Company and LG Chem, Ltd., dated as of November 6, 2018 (Filed With SEC on November 13, 2018)

Executive Employment Agreement between the Registrant and Bethany Mancilla dated as of June 22, 2018 (Filed With SEC on August 13, 2018)

Executive Employment Agreement between the Registrant and Anish Suri dated as of April, 2018 (Filed With SEC on August 13, 2018)

First Amendment to License Agreement between the Registrant and MIL 21E, LLC dated June 18, 2018 (Filed With SEC on June 20, 2018)

Warrant issued to MDB Capital Group, LLC (U2017-1) dated December 27, 2017 (Filed With SEC on March 29, 2018)

Warrant issued to Feltl and Company, Inc. (U2017-2) dated December 27, 2017 (Filed With SEC on March 29, 2018)

Warrant issued to Paulson Investment Company LLC (U2017-3) dated December 27, 2017 (Filed With SEC on March 29, 2018)

License Agreement between the Registrant and MIL 21E, LLC dated January 19, 2018 (Filed With SEC on March 29, 2018)

Amended and Restated License Agreement by and between the Registrant and Albert Einstein College of Medicine dated July 31, 2017 (Filed With SEC on December 13, 2017)

Exclusive Patent License and Research Collaboration Agreement between the Registrant and Merck Sharp & Dohme Corp. dated November 14, 2017 (Filed With SEC on December 13, 2017)

Amended and Restated License Agreement by and between the Registrant and Albert Einstein College of Medicine dated July 31, 2017 (Filed With SEC on December 11, 2017)

Exclusive Patent License and Research Collaboration Agreement between the Registrant and Merck Sharp & Dohme Corp. dated November 14, 2017 (Filed With SEC on December 11, 2017)

Form of Subscription Agreement for the offering (Filed With SEC on December 5, 2017)

Form of Underwriting Agreement (Filed With SEC on December 5, 2017)

Specimen Certificate representing shares of common stock of the Registrant (Filed With SEC on December 5, 2017)

Form of Underwriters Warrant (Filed With SEC on December 5, 2017)

Form of Lock-Up Agreement (Filed With SEC on December 5, 2017)

Escrow Agreement for the offering by and between the Registrant, MDB Capital Group, LLC and Continental Stock Transfer & Trust Company dated November 24, 2017 (Filed With SEC on December 5, 2017)

Exclusive Patent License and Research Collaboration Agreement between the Registrant and Merck Sharp & Dohme Corp. dated November 14, 2017 (Filed With SEC on December 5, 2017)

Executive Employment Agreement between the Registrant and Colin G. Sandercock dated as of November 15, 2017 (Filed With SEC on December 5, 2017)

Form of Irrevocable Waiver and Amendment to Securities Purchase Agreements between the Registrant and investors for offerings completed June 15, 2015 and December 22, 2016 (Filed With SEC on December 5, 2017)

Executive Employment Agreement between the Registrant and Rodolfo J. Chaparro dated effective June 15, 2015 (Filed With SEC on September 21, 2017)

Warrant to Purchase Common Stock issued to the placement agent in the Registrants 2015 private placement offering (Filed With SEC on September 21, 2017)

Engagement Agreement dated April 13, 2015 between the Registrant and MDB Capital Group, LLC (Filed With SEC on September 21, 2017)

Form of Securities Purchase Agreement between the Registrant and investors for an offering completed on June 15, 2015 (Filed With SEC on September 21, 2017)

Form of Registration Rights Agreement between the Registrant and investors for an offering completed on June 15, 2015 (Filed With SEC on September 21, 2017)

Form of Securities Purchase Agreement between the Registrant and investors for an offering completed on December 22, 2016 (Filed With SEC on September 21, 2017)

Form of Joinder and Amendment to Registration Rights Agreement between the Registrant and investors for an offering completed on December 22, 2016 (Filed With SEC on September 21, 2017)

Amended and Restated License Agreement by and between the Registrant and Albert Einstein College of Medicine dated July 31, 2017 (Filed With SEC on September 21, 2017)

Executive Employment Agreement between the Registrant and Ronald D. Seidel dated effective June 15, 2015 (Filed With SEC on September 21, 2017)

Employment Agreement between the Registrant and Daniel R. Passeri dated August 29, 2016 (Filed With SEC on September 21, 2017)

Form of Indemnification Agreement (Filed With SEC on September 21, 2017)

Second Amendment to Real Estate License Agreement by and between the Registrant and Mass Innovation Labs, LLC dated June 28, 2017 (Filed With SEC on September 21, 2017)

Amendment to Real Estate License Agreement by and between the Registrant and Mass Innovation Labs, LLC dated November 14, 2016 (Filed With SEC on September 21, 2017)

Real Estate License Agreement by and between the Registrant and Mass Innovation Labs, LLC dated July 29, 2015 (Filed With SEC on September 21, 2017)

Form of stock option award under 2016 Non-Employee Equity Incentive Plan (Filed With SEC on September 21, 2017)

Cue Biopharma, Inc. 2016 Non-Employee Equity Incentive Plan (Filed With SEC on September 21, 2017)

Form of stock option award under 2016 Omnibus Incentive Plan (Filed With SEC on September 21, 2017)

Cue Biopharma, Inc. 2016 Omnibus Incentive Plan, as amended and restated (Filed With SEC on September 21, 2017)

Category

Industry

Companies

Contracts

Cue Biopharma, Inc. Contracts & Agreements